Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel review beckons.
Our latest articles
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
A front-line trial yields a positive result two years after the drug got a US complete response letter.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
The usually conservative group spends big on Dicerna – but others might be interested too.